🟩 Lazerib 80 mg
Generic Name: Lazeritinib Mesylate Hydrate INN
Brand Name: Lazerib
Manufacturer: Everest Pharmaceuticals Ltd.
Strength & Form: 80 mg | Film-coated tablets
Pack Size: 90 tablets
📌 Indications:
Lazerib (Lazeritinib) is indicated for the treatment of patients with non-small cell lung cancer (NSCLC) that is:
-
Locally advanced or metastatic
-
Harboring epidermal growth factor receptor (EGFR) mutations
-
Especially effective in patients who have developed resistance to previous EGFR-targeted therapies.
💊 Pharmacology:
-
Lazeritinib is a third-generation EGFR tyrosine kinase inhibitor (TKI).
-
It selectively inhibits both EGFR sensitizing mutations and the T790M resistance mutation, which is the most common cause of acquired resistance to first/second generation TKIs.
-
It helps block cancer cell proliferation and promotes apoptosis in tumor cells.
-
Lazerib also shows good blood-brain barrier penetration, making it effective against CNS metastases.
💉 Dosage & Administration:
-
Recommended dose: 80 mg once daily, orally.
-
Can be taken with or without food.
-
Treatment should be continued until disease progression or unacceptable toxicity.
⚠️ Tablets should be swallowed whole — not crushed or chewed.
⚠️ Precautions & Warnings:
-
Monitor for interstitial lung disease (ILD)/pneumonitis.
-
Risk of QT prolongation – ECG monitoring may be required.
-
Regular liver function tests recommended.
-
Dose adjustments may be necessary in case of toxicity.
❌ Contraindications:
🤰 Pregnancy & Lactation:
-
May cause fetal harm if administered during pregnancy.
-
Women of childbearing potential should use effective contraception.
-
Not recommended during breastfeeding.
⚕️ Side Effects:
Common:
Serious:
🧊 Storage Conditions:
-
Store below 30°C, in a dry place.
-
Protect from light and moisture.
-
Keep out of reach of children.